This report was first published by Endpoints News. To see the original version, click here
Another GLP-1 drug is up for Medicare negotiations under the Inflation Reduction Act.
Eli Lilly’s GLP-1 diabetes drug Trulicity is among 15 drugs selected for the third round of negotiations. Gilead’s HIV drug Biktarvy was also selected. The two drugs were used by 617,000 and 101,000 Medicare enrollees, respectively, from November 2024 through October 2025, CMS said.
您已阅读12%（458字），剩余88%（3411字）包含更多重要信息，订阅以继续探索完整内容，并享受更多专属服务。